Ezalife's Button Huggie device shows 77% reduction in feeding tube dislodgement & 270% higher caregiver satisfaction. FDA-registered, patent-protected innovationEzalife's Button Huggie device shows 77% reduction in feeding tube dislodgement & 270% higher caregiver satisfaction. FDA-registered, patent-protected innovation

Ezalife Device Shows 77% Reduction in Feeding Tube Dislodgement in Clinical Results

2026/04/03 10:30
Okuma süresi: 2 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen [email protected] üzerinden bizimle iletişime geçin.

Ezalife announced clinical results showing its Button Huggie device achieved a 77% reduction in feeding tube dislodgement, addressing what the company describes as a long-standing challenge in patient care. Feeding tubes, commonly secured with tape and gauze, have remained largely unchanged for decades, often leading to discomfort, complications, and emergency interventions. The company’s solution introduces a purpose-built, FDA-registered device designed to stabilize G-buttons more effectively.

In addition to clinical improvements, Ezalife reported strong patient and caregiver satisfaction metrics, including an approximately 270% increase in parent satisfaction compared to traditional methods and a Net Promoter Score of 76, significantly higher than the industry average of 46. ‘These results highlight both the clinical effectiveness and the real-world impact on families,’ the company stated. ‘We’re not just improving outcomes; we’re improving daily life.’

The Button Huggie is protected by a granted U.S. patent with 18 claims, along with additional international patents across Europe, the UK, Canada, China, and Japan, reinforcing Ezalife’s position as a category innovator. By addressing a critical yet underserved segment of the $1.9 billion feeding tube market, Ezalife is positioning itself as a disruptive force in post-operative and long-term care.

As its StartEngine campaign approaches its April 6 close, the company continues to attract attention from investors seeking opportunities at the intersection of healthcare innovation and proven clinical validation. Ezalife develops precision-engineered medical devices to improve the safety and quality of life for patients requiring feeding tubes, with a mission to replace outdated standards of care with innovative, patient-centered solutions.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Ezalife Device Shows 77% Reduction in Feeding Tube Dislodgement in Clinical Results.

The post Ezalife Device Shows 77% Reduction in Feeding Tube Dislodgement in Clinical Results appeared first on citybuzz.

Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

$30,000 in PRL + 15,000 USDT

$30,000 in PRL + 15,000 USDT$30,000 in PRL + 15,000 USDT

Deposit & trade PRL to boost your rewards!